• Explore /
  • Poster
  • / Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Phase 2 results.

Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Phase 2 results.

Abstract Poster

Authors

null

Dmitriy Zamarin

Memorial Sloan Kettering Cancer Center, New York, NY

Dmitriy Zamarin , Kunle Odunsi , Emese Zsiros , Brian M. Slomovitz , Agustin Pimentel , Linda R. Duska , Matthew Reilley , John J. Nemunaitis , Danae M. Hamouda , Hitendra Patel , Neil Howard Segal , Giulio Pesci , Aliya Holland , Lisa Shohara , Paul Otto Schwarzenberger , Toni Ricciardi , Mary J. Macri , Aileen Ryan , Magnus Erik Jaderberg , Ralph Rudolph Venhaus

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

PD1/PD-L1 Inhibitor Combinations

Clinical Trial Registration Number

NCT02963831

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 2600)

DOI

10.1200/JCO.2022.40.16_suppl.2600

Abstract #

2600

Poster Bd #

255

Abstract Disclosures

Similar Posters

First Author: Shuiling Jin

First Author: Zhichao Jiang

First Author: Robin Kate Kelley

First Author: Akihisa Matsuda